Poxel
Biopharma developing treatments for metabolic diseases, with a product marketed in Japan.
POXEL | PA
Overview
Corporate Details
- ISIN(s):
- FR0012432516
- LEI:
- 9695003OIX0T7NX72N26
- Country:
- France
- Address:
- 259 AVENUE JEAN JAURES, 69007 LYON
Description
Poxel is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The company's pipeline features two mid-stage candidates: PXL065, a deuterium-stabilized R-pioglitazone for NASH that has completed a Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator for rare diseases. Additionally, Poxel's product TWYMEEG® (Imeglimin) is approved and marketed in Japan by Sumitomo Pharma for the treatment of type 2 diabetes, providing the company with royalties and sales-based payments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-29 08:00 |
Inside Information / Other news releases
|
English | PDF • 76.8 KB | ||
| 2025-09-29 08:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 95.9 KB | ||
| 2025-08-08 17:45 |
Inside Information / Other news releases
|
English | PDF • 109.8 KB | ||
| 2025-08-08 17:45 |
Informations privilégiées / Autres communiqués
|
French | PDF • 96.7 KB | ||
| 2025-08-01 07:30 |
Inside Information / Other news releases
|
English | PDF • 134.8 KB | ||
| 2025-08-01 07:30 |
Informations privilégiées / Autres communiqués
|
French | PDF • 164.3 KB | ||
| 2025-07-29 20:16 |
Informations privilégiées / Autres communiqués
|
French | PDF • 161.1 KB | ||
| 2025-07-29 20:16 |
Inside Information / Other news releases
|
English | PDF • 201.8 KB | ||
| 2025-07-08 18:46 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 110.8 KB | ||
| 2025-06-30 18:32 |
Inside Information / Other news releases
|
English | PDF • 109.4 KB | ||
| 2025-06-30 18:32 |
Informations privilégiées / Autres communiqués
|
French | PDF • 95.0 KB | ||
| 2025-06-19 17:46 |
Inside Information / Other news releases
|
English | PDF • 147.7 KB | ||
| 2025-06-19 17:46 |
Informations privilégiées / Autres communiqués
|
French | PDF • 136.3 KB | ||
| 2025-06-06 19:05 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 76.2 KB | ||
| 2025-05-28 07:30 |
Inside Information / Other news releases
|
English | PDF • 95.0 KB |
Automate Your Workflow. Get a real-time feed of all Poxel filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Poxel
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Poxel via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-29 | N/A | Other | Buy | 80,000 | N/A |
Peer Companies
